Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J1071
1 MG
Medicare payment limit per unit (Q4 2026): $0.023
| Setting | Max units / day | Adjudication (MAI) | CMS rationale |
|---|---|---|---|
| Practitioner services (professional claims) | 400 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Prescribing Information |
| Facility outpatient hospital services | 400 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Prescribing Information |
| DME supplier services | 0Not reportable in this setting | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. |
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Current Medicare Part B payment limit · Q4 2026
$0.023per 1 MG
Effective Oct 1, 2026 – Dec 31, 2026 · ASP methodology (per CMS file) · based on Q2 2026 ASP data · coinsurance 20.000%
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $0.023 | 1 MG | 20% | −8.0% | — |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $0.025 | 1 MG | 20% | +4.2% |
Medicare hospital outpatient (OPPS) · Q4 2026
N Packaged: no separate payment
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Derived $ / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|---|
| 50090-4147-00 | Testosterone CypionateA-S Medication Solutions | 10 × 1 | 2,000 | 2,000 | $46.00 | ASP | Q4 2021 – Q4 2026 | ListedTestosterone Cypionate |
| 50090-4446-00 | Testosterone CypionateA-S Medication Solutions | 10 × 1 | 2,000 | 2,000 | $46.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingTestosterone Cypionate |
| 50090-4920-00 | Testosterone CypionateA-S Medication Solutions | 10 × 1 | 2,000 | 2,000 | $46.00 | ASP | Q1 2021 – Q4 2026 | ListedTestosterone Cypionate |
| 50090-4921-00 | Testosterone CypionateA-S Medication Solutions | 10 × 1 | 2,000 | 2,000 | $46.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingTestosterone Cypionate |
| 00591-4128-79 | Testosterone CypionateActavis Pharma, Inc. | 10 × 1 | 2,000 | 2,000 | $46.00 | ASP | Q1 2021 – Q4 2026 | Excluded listingTestosterone Cypionate |
| 47781-0910-91 | Testosterone CypionateAlvogen, Inc. | 10 × 10 | 2,000 | 20,000 | $460.00 | ASP | Q3 2023 – Q4 2026 | ListedTestosterone Cypionate |
| 47781-0911-93 | Testosterone CypionateAlvogen, Inc. | 1 × 1 | 200 | 200 | $4.60 | ASP | Q4 2023 – Q4 2026 | ListedTestosterone Cypionate |
| 69097-0536-37 | Testosterone CypionateCipla USA, Inc. | 10 × 1 | 1,000 | 1,000 | $23.00 | ASP | Q1 2021 – Q4 2026 | ListedTestosterone Cypionate |
| 69097-0537-31 | Testosterone CypionateCipla USA, Inc. | 1 × 1 | 200 | 200 | $4.60 | ASP | Q1 2021 – Q4 2026 | ListedTestosterone Cypionate |
| 69097-0802-32 | Testosterone CypionateCipla USA, Inc. | 1 × 1 | 200 | 200 | $4.60 | ASP | Q1 2021 – Q4 2026 | ListedTestosterone Cypionate |
| 69097-0802-37 | Testosterone CypionateCipla USA, Inc. | 10 × 1 | 2,000 | 2,000 | $46.00 | ASP | Q1 2021 – Q4 2026 | ListedTestosterone Cypionate |
| 55150-0276-01 | Testosterone CypionateEugia US LLC | 10 × 1 | 1,000 | 1,000 | $23.00 | ASP | Q2 2024 – Q4 2026 | ListedTestosterone Cypionate |
| 55150-0277-01 | Testosterone CypionateEugia US LLC | 1 × 1 | 200 | 200 | $4.60 | ASP | Q2 2024 – Q4 2026 | ListedTestosterone Cypionate |
| 55150-0278-01 | Testosterone CypionateEugia US LLC | 10 × 1 | 2,000 | 2,000 | $46.00 | ASP | Q2 2024 – Q4 2026 | ListedTestosterone Cypionate |
| 00143-9005-01 | Testosterone CypionateHikma Pharmaceuticals USA Inc. | 10 × 1 | 2,000 | 2,000 | $46.00 | ASP | Q3 2022 – Q4 2026 | ListedTestosterone Cypionate |
| 00143-9659-01 | Testosterone CypionateHikma Pharmaceuticals USA Inc. | 1 × 1 | 200 | 200 | $4.60 | ASP | Q1 2021 – Q4 2026 | ListedTestosterone Cypionate |
| 00143-9726-01 | Testosterone CypionateHikma Pharmaceuticals USA Inc. | 10 × 1 | 2,000 | 2,000 | $46.00 | ASP | Q1 2021 – Q4 2026 | ListedTestosterone Cypionate |
| 72603-0286-01 | Testosterone CypionateNorthstar RxLLC | 1 × 1 | 200 | 200 | $4.60 | ASP | Q3 2025 – Q4 2026 | ListedTestosterone Cypionate |
| 00574-0820-01 | Testosterone CypionatePadagis US LLC | 1 × 1 | 200 | 200 | $4.60 | ASP | Q1 2021 – Q4 2026 | ListedTestosterone Cypionate |
| 00574-0820-10 | Testosterone CypionatePadagis US LLC | 10 × 1 | 2,000 | 2,000 | $46.00 | ASP | Q1 2021 – Q4 2026 | ListedTestosterone Cypionate |
| 00574-0827-10 | Testosterone CypionatePadagis US LLC | 10 × 1 | 2,000 | 2,000 | $46.00 | ASP | Q1 2021 – Q4 2026 | ListedTestosterone Cypionate |
| 00009-0085-10 | Depo-TestosteronePfizer Inc | 10 × 1 | 1,000 | 1,000 | $23.00 | ASP | Q1 2021 – Q4 2026 | ListedDepo-Testosterone |
| 00009-0086-01 | Depo-TestosteronePfizer Inc | 1 × 1 | 200 | 200 | $4.60 | ASP | Q1 2021 – Q4 2026 | ListedDepo-Testosterone |
| 00009-0347-02 | Depo-TestosteronePfizer Inc | 10 × 1 | 1,000 | 1,000 | $23.00 | ASP | Q1 2021 – Q4 2026 | ListedDepo-Testosterone |
| 00009-0417-01 | Depo-TestosteronePfizer Inc | 1 × 1 | 200 | 200 | $4.60 | ASP | Q1 2021 – Q4 2026 | ListedDepo-Testosterone |
| 00009-0417-02 | Depo-TestosteronePfizer Inc | 10 × 1 | 2,000 | 2,000 | $46.00 | ASP | Q1 2021 – Q4 2026 | ListedDepo-Testosterone |
| 00409-6557-01 | Testosterone CypionatePfizer Inc | 10 × 1 | 1,000 | 1,000 | $23.00 | ASP | Q1 2021 – Q4 2026 | ListedTestosterone Cypionate |
| 00409-6562-01 | Testosterone CypionatePfizer Inc | 1 × 1 | 200 | 200 | $4.60 | ASP | Q1 2021 – Q4 2026 | ListedTestosterone Cypionate |
| 00409-6562-20 | Testosterone CypionatePfizer Inc | 10 × 1 | 2,000 | 2,000 | $46.00 | ASP | Q1 2021 – Q4 2026 | ListedTestosterone Cypionate |
| 70700-0288-22 | Testosterone CypionateXiromed, LLC | 10 × 1 | 1,000 | 1,000 | $23.00 | ASP | Q1 2024 – Q4 2026 | ListedTestosterone Cypionate |
| 70700-0289-22 | Testosterone CypionateXiromed, LLC | 1 × 1 | 200 | 200 | $4.60 | ASP | Q1 2024 – Q4 2026 | ListedTestosterone Cypionate |
| 70700-0290-22 | Testosterone CypionateXiromed, LLC | 10 × 1 | 2,000 | 2,000 | $46.00 | ASP | Q4 2024 – Q4 2026 | ListedTestosterone Cypionate |
Derived calculation “Derived $ / NDC” = billable units per NDC × the current payment limit. It is arithmetic for orientation, not a payment amount.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 69097-0537-37 | Testosterone CypionateCIPLA USA INC. | 10 × 1 | 2,000 | 2,000 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 2015 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| CMS Policy |
An MUE is the most units CMS expects for this code for one patient on one date of service by the same provider in most correctly reported claims. CMS MUE program
| — |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $0.024 | 1 MG | 20% | −11.1% | — |
|---|
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $0.027 | 1 MG | 20% | −3.6% | — |
|---|
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $0.028 | 1 MG | 20% | −9.7% | — |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $0.031 | 1 MG | 20% | +3.3% | — |
|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $0.030 | 1 MG | 20% | −6.3% | — |
|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $0.032 | 1 MG | 20% | +0.0% | — |
|---|
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $0.032 | 1 MG | 20% | +3.2% | — |
|---|
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $0.031 | 1 MG | 20% | +210.0% | — |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $0.010 | 1 MG | 20% | −63.0% | — |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $0.027 | 1 MG | 20% | −6.9% | — |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $0.029 | 1 MG | 20% | +0.0% | — |
|---|
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $0.029 | 1 MG | 20% | +0.0% | — |
|---|
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $0.029 | 1 MG | 20% | −9.4% | — |
|---|
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $0.032 | 1 MG | — | +10.3% | — |
|---|
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $0.029 | 1 MG | — | +0.0% | — |
|---|
| Q3 2022 | Jul 1, 2022 – Sep 30, 2022 | $0.029 | 1 MG | — | +3.6% | — |
|---|
| Q2 2022 | Apr 1, 2022 – Jun 30, 2022 | $0.028 | 1 MG | — | +7.7% | — |
|---|
| Q1 2022 | Jan 1, 2022 – Mar 31, 2022 | $0.026 | 1 MG | — | −10.3% | — |
|---|
| Q4 2021 | Oct 1, 2021 – Dec 31, 2021 | $0.029 | 1 MG | — | +3.6% | — |
|---|
| Q3 2021 | Jul 1, 2021 – Sep 30, 2021 | $0.028 | 1 MG | — | +0.0% | — |
|---|
| Q2 2021 | Apr 1, 2021 – Jun 30, 2021 | $0.028 | 1 MG | — | −15.2% | — |
|---|
| Q1 2021 | Jan 1, 2021 – Mar 31, 2021 | $0.033 | 1 MG | — | — | — |
|---|
| 00009-0086-10 | Depo-TestosteronePfizer Inc | 10 × 1 | 2,000 | 2,000 | ASP | Q1 2021 – Q1 2026Not in Q4 2026 file | Excluded listingDepo-Testosterone |
|---|
| 00409-6562-02 | Testosterone CypionatePfizer Inc | 1 × 1 | 200 | 200 | ASP | Q1 2021 – Q1 2026Not in Q4 2026 file | Excluded listingTestosterone Cypionate |
|---|
| 00409-6562-22 | Testosterone CypionatePfizer Inc | 10 × 1 | 2,000 | 2,000 | ASP | Q1 2021 – Q1 2026Not in Q4 2026 file | Excluded listingTestosterone Cypionate |
|---|
| 00009-0520-01 | Testosterone CypionatePFIZER INC. | 1 × 1 | 200 | 200 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingDepo-Testosterone |
|---|
| 62756-0015-40 | Testosterone CypionateSun Pharmaceutical Industries, Inc. | 1 × 1 | 200 | 200 | ASP | Q1 2021 – Q1 2026Not in Q4 2026 file | ListedTestosterone Cypionate |
|---|
| 62756-0016-40 | Testosterone CypionateSun Pharmaceutical Industries, Inc. | 10 × 1 | 2,000 | 2,000 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedTestosterone Cypionate |
|---|
| 62756-0017-40 | Testosterone CypionateSun Pharmaceutical Industries, Inc. | 10 × 1 | 1,000 | 1,000 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedTestosterone Cypionate |
|---|